Abstract
Serum prostate-specific antigen is credited with dramatic advances in the early detection, screening, and management of men with prostatic carcinoma. There has been more than a twofold increase in the number of men diagnosed during the last decade, and prostate cancer has emerged as the most common non-skin cancer and the second leading cause of cancer death in men. This report summarizes the history and current status of prostate-specific antigen and other serum markers, incorporating consensus opinions from the Second International Consultation on Prostate Cancer held in Paris in June 1999.
MeSH terms
-
Age Factors
-
Antigens, Surface*
-
Biomarkers, Tumor / blood*
-
Carboxypeptidases / blood
-
Glutamate Carboxypeptidase II
-
Humans
-
Insulin-Like Growth Factor I / analysis
-
Lymphatic Metastasis
-
Male
-
Neoplasm Staging
-
Prostate-Specific Antigen / blood*
-
Prostate-Specific Antigen / chemistry
-
Prostatic Neoplasms / blood*
-
Prostatic Neoplasms / pathology
-
Reference Values
-
Reverse Transcriptase Polymerase Chain Reaction
-
World Health Organization
Substances
-
Antigens, Surface
-
Biomarkers, Tumor
-
Insulin-Like Growth Factor I
-
Carboxypeptidases
-
FOLH1 protein, human
-
Glutamate Carboxypeptidase II
-
Prostate-Specific Antigen